Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) was the recipient of a significant growth in short interest during the month of July. As of July 31st, there was short interest totalling 1,528,685 shares, a growth of 32.2% from the July 14th total of 1,156,211 shares. Based on an average daily volume of 124,447 shares, the short-interest ratio is currently 12.3 days. Approximately 5.3% of the company’s stock are short sold.
GNMX has been the topic of a number of research analyst reports. UBS AG reaffirmed a “positive” rating on shares of Aevi Genomic Medicine in a report on Wednesday, May 10th. Jefferies Group LLC reaffirmed a “hold” rating and set a $1.50 target price on shares of Aevi Genomic Medicine in a report on Friday, May 12th. Finally, ValuEngine downgraded Aevi Genomic Medicine from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.
Aevi Genomic Medicine (NASDAQ GNMX) opened at 1.315 on Friday. The company’s market cap is $48.80 million. Aevi Genomic Medicine has a 12-month low of $0.98 and a 12-month high of $17.75. The firm’s 50-day moving average price is $1.28 and its 200-day moving average price is $2.40.
Aevi Genomic Medicine (NASDAQ:GNMX) last issued its quarterly earnings results on Wednesday, May 10th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by $0.02. Analysts expect that Aevi Genomic Medicine will post ($1.04) EPS for the current year.
A number of institutional investors have recently modified their holdings of GNMX. State Street Corp raised its position in shares of Aevi Genomic Medicine by 15.4% in the fourth quarter. State Street Corp now owns 345,698 shares of the biotechnology company’s stock valued at $1,789,000 after buying an additional 46,149 shares in the last quarter. Teachers Advisors LLC purchased a new position in shares of Aevi Genomic Medicine during the fourth quarter valued at about $204,000. Birchview Capital LP raised its position in shares of Aevi Genomic Medicine by 41.7% in the first quarter. Birchview Capital LP now owns 68,000 shares of the biotechnology company’s stock valued at $126,000 after buying an additional 20,000 shares in the last quarter. TIAA CREF Investment Management LLC raised its position in shares of Aevi Genomic Medicine by 16.7% in the first quarter. TIAA CREF Investment Management LLC now owns 97,719 shares of the biotechnology company’s stock valued at $182,000 after buying an additional 13,966 shares in the last quarter. Finally, LMR Partners LLP purchased a new position in shares of Aevi Genomic Medicine during the second quarter valued at about $149,000. Hedge funds and other institutional investors own 27.97% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://transcriptdaily.com/2017/08/13/aevi-genomic-medicine-inc-nasdaqgnmx-short-interest-update.html.
About Aevi Genomic Medicine
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease.
Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.